{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-276135","form_type":"8-K","ticker":"MGX","cik":"0001785279","company_name":"Metagenomi Therapeutics, Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.450038+00:00","generated_at":"2026-05-16T21:22:39.807415+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Metagenomi Q3: $184.1M cash, 25% workforce cut, CEO change, MGX-001 data positive","bullets":["Cash, equivalents, and marketable securities $184.1M as of Sep 30, 2025; runway extended into Q4 2027.","Workforce reduced by 25%; early discovery and platform research deprioritized.","Jian Irish promoted to CEO; founder Brian Thomas remains on Board; Willard Dere named Board Chair.","MGX-001 hemophilia A preclinical data: curative FVIII activity in NHPs at proposed clinical dose averaging 49%.","Pre-IND meeting expected Q4 2025; IND/CTA submissions targeted for Q4 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-276135","json":"https://secwatch.observer/filing/0001193125-25-276135.json","markdown":"https://secwatch.observer/filing/0001193125-25-276135.md","text":"https://secwatch.observer/filing/0001193125-25-276135.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785279/000119312525276135/0001193125-25-276135-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785279/000119312525276135/mgx-20251111.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:22:39.807415+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}